BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22792233)

  • 1. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.
    Winter JM; Tang LH; Klimstra DS; Brennan MF; Brody JR; Rocha FG; Jia X; Qin LX; D'Angelica MI; DeMatteo RP; Fong Y; Jarnagin WR; O'Reilly EM; Allen PJ
    PLoS One; 2012; 7(7):e40157. PubMed ID: 22792233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
    Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
    Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
    Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
    Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
    Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
    Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
    [No Abstract]   [Full Text] [Related]  

  • 5. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
    Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
    Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning.
    Yokoyama S; Hamada T; Higashi M; Matsuo K; Maemura K; Kurahara H; Horinouchi M; Hiraki T; Sugimoto T; Akahane T; Yonezawa S; Kornmann M; Batra SK; Hollingsworth MA; Tanimoto A
    Clin Cancer Res; 2020 May; 26(10):2411-2421. PubMed ID: 31992588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
    Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biphasic Alterations in Expression and Subcellular Localization of MUC1 in Pancreatic Ductal Carcinogenesis in Syrian Hamsters.
    Kitahashi T; Takahashi M; Imai T
    Pancreas; 2015 Jan; 44(1):76-86. PubMed ID: 25036908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma.
    Silva EM; Begnami MD; Fregnani JH; Pelosof AG; Zitron C; Montagnini AL; Soares FA
    Gastric Cancer; 2008; 11(3):149-59. PubMed ID: 18825309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance.
    Zhang HK; Zhang QM; Zhao TH; Li YY; Yi YF
    World J Gastroenterol; 2004 Oct; 10(20):3044-7. PubMed ID: 15378790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
    Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
    Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
    Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
    Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.
    Adsay NV; Merati K; Andea A; Sarkar F; Hruban RH; Wilentz RE; Goggins M; Iocobuzio-Donahue C; Longnecker DS; Klimstra DS
    Mod Pathol; 2002 Oct; 15(10):1087-95. PubMed ID: 12379756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.
    Duncan TJ; Watson NF; Al-Attar AH; Scholefield JH; Durrant LG
    World J Surg Oncol; 2007 Mar; 5():31. PubMed ID: 17349047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
    Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
    Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
    HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
    Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
    Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.